Page 229 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 229

                                Abstracts/presentations
• Marc Huisman, Ronald Boellaard, Josée Zijlstra, Daphne de Jong, Danielle Vugts, Sonja Zweegman, Otto Hoekstra, Guus van Dongen, Yvonne Jauw. Beyond SUV: from false-positive to true positive tumor uptake of 89Zr- antiCD20. Oral presentation. Society of Nuclear Medicine & Molecular Imaging Annual Meeting, Anaheim, USA, 2019.
• Yvonne W.S. Jauw, Joseph A. O’Donoghue, Josée M. Zijlstra, Otto S. Hoekstra, C. Willemien Menke-van der Houven van Oordt, Franck Morschhauser, Jorge A. Carrasquillo, Sonja Zweegman, Neeta Pandit-Taskar, Adriaan A. Lammertsma, Guus A.M.S. van Dongen, Ronald Boellaard, Wolfgang A. Weber, Marc Huisman. 89Zr-immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo. Poster presentation. Society of Nuclear Medicine & Molecular Imaging Annual Meeting, Anaheim, USA, 2019. Poster award candidate, Oncology track.
• Keiichi Magota, Yvonne W.S. Jauw, Dennis F. Heijtel, Josée M. Zijlstra, Guus A.M.S. van Dongen, Adriaan A. Lammertsma, Ronald Boellaard, Marc C. Huisman. Optimizing iterative reconstruction settings for improved 89Zr- immuno-PET image quality. Poster presentation. European Association of Nuclear Medicine Annual Congress, Dusseldorf, Germany, 2018.
• Yvonne W.S. Jauw, Catharina W. Menke-van der Houven van Oordt, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Adriaan A. Lammertsma, Henk M.W. Verheul, Guus A.M.S. van Dongen, Otto S. Hoekstra, Marc C. Huisman. In-vivo assessment of antibody selectivity: immuno-PET with anti-CD44 antibody in a phase I clinical trial. Oral presentation. Society of Nuclear Medicine & Molecular Imaging, Annual Meeting, Denver, USA, 2017. Selected for Highlight Session, Oncology track.
• Yvonne Jauw, Josée Zijlstra, Otto S. Hoekstra, Sonja Zweegman, Pascal Odou, Danielle Vugts, Damien Huglo, Franck Morschhauser, Marc Huisman. First- in-human in-vivo biodistribution of a glyco-engineered antibody: 89Zirconium- labeled obinutuzumab in patients with non-Hodgkin lymphoma. Oral presentation. Society of Nuclear Medicine & Molecular Imaging Annual Meeting, Denver, USA, 2017.
A
List of publications
A
  227

























































































   227   228   229   230   231